Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of February 2023. The filing, dated February 9, 2023, serves primarily to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document acts as a conduit for the attached press release rather than a standalone financial report.
Material Changes
No material financial changes versus prior periods are detailed within the body of this Form 6-K. The filing indicates that the substantive information regarding any updates is contained in the press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, management commentary, risk factors, or details on contingencies. These elements, if present, are located in the referenced press release (Exhibit 99.1) which is incorporated by reference into the company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Review the full text of the press release dated February 9, 2023 (Exhibit 99.1) for the actual content of the announcement.
- Verify the impact of the announcement on the company's registration statements (Form F-3 No. 333-255089 and Form S-8 No. 333-255124).
- Note that this Form 6-K contains no standalone financial figures or operational metrics.